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Objectives: To assess the relative efficacy and safety of canagliflozin (CANA), a sodium-
glucose co-transporter (SGLT) inhibitor, as add-on to metformin, compared to sulpho-
nylureas (SU), pioglitazone, DPP-4s, GLP-1s and dapagliflozin. MethOds: Bayesian 
network meta-analysis was conducted based on a systematic literature review described 
separately. Outcomes of interest included HbA1c, weight and hypoglycaemia. Networks 
were based on treatment- and dose-specific nodes where possible. Non-informative 
priors were used; selection of fixed versus random-effect model was based on DIC. 
Studies causing inconsistency (identified through the comparison of direct and indirect 
evidence in the network) were identified with a clinical expert and excluded from the 
base case. Results: 25/17/7 studies reported results at 26/52/104 weeks (w) respectively. 
HbA1c-reduction (2) at 26w/52w was best for exenatide 2mg and liraglutide 1.8mg. CANA 
300mg had a higher reduction versus DPP-4s (h= -0.11 to -0.39) and dapagliflozin 10mg 
(= = -0.12 to -0.38) across all time points; while CANA 100mg conferred at least as large 
reductions (= = 0.01 to -0.30 and 0.00 to -0.26 respectively). The analysis at 104w was 
conducted based on the pooling of SUs. CANA 300mg and 100mg ranked first/second 
before liraglutide 1.2mg/1.8mg (s= -0.11/-0.13 and -0.02/-0.04 respectively). Both CANA 
doses had higher weight-reductions than SU, DPP-4s and pioglitazone, and provided 
reductions comparable to GLP-1s and dapagliflozin. Odds ratios for hypoglycaemia ver-
sus SU ranged from 0.03 to 0.11 for DPP-4 and SGLT. cOnclusiOns: NMA of add-on 
therapies to metformin suggests that CANA 300mg is associated with increased HbA1c-
reduction versus DPP-4s and dapagliflozin while CANA 100mg provides at least similar 
effects. Additionally, results suggest increasing relative efficacy of CANA over time versus 
liraglutide and CANA reached at least as large HbA1c reductions as liraglutide at 104w. 
Weight reduction was comparable to GLP-1s and substantially higher than all other 
classes. All classes showed significantly less risk of hypoglycaemia compared to SU.
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Objectives: Claims data are often used to estimate the prevalence of chronic dis-
eases, typically by dividing the number of patients with disease-related claims 
(e.g., ≥ 1 or ≥ 2 claims) by the number of studied individuals. Such estimates will 
have a downward bias because not all diseased patients will generate disease-
related claims within their enrollment period. This downward bias can be sub-
stantial for underserved diseases that lack effective treatments. We explored 
whether an empirical Bayes estimator for the number of diseased individuals who 
do not generate claims could improve the accuracy of claims-based prevalence 
estimates. MethOds: As an example, we studied the prevalence of a rare der-
matological condition without any FDA-approved therapies. After accounting for 
enrollment time, individuals in a large nation-wide claims database were identified 
as having 0, 1, 2, 3, etc., disease-related claims. These counts were modeled using a 
mixture of Poisson distributions, with an unknown mixing distribution. Empirical 
Bayes approaches, which are frequently used to estimate numbers of unobserved 
species in ecological experiments, were used to estimate the number of diseased 
individuals without claims, and to provide adjusted prevalence estimates. Results: 
Out of over 4 million individuals with at least one year of continuous enrollment, 
n= 2,026 had disease-related claims, comprised of n= 1,422 with one claim, n= 317 
with two claims, n= 134 with 3 claims, etc. The traditional method for estimating 
prevalence identified 4.9 cases per 10,000 persons. After applying the empirical 
Bayes approach, the estimated prevalence increased to 7.9 cases per 10,000 persons, 
and became closer to published prevalence estimates based on non-claims data 
sources. cOnclusiOns: In this example application, prevalence estimates based 
on claims data were increased by over 60% by using empirical Bayes approaches to 
account for large numbers of diseased individuals who did not generate claims. The 
increased prevalence estimates were more consistent with the published literature.
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Objectives: To analyse the applicability of copulas distribution in economic evalu-
ation. MethOds: We have analyzed data from an observational prospective study 
of patients with allergic rhinitis in Spain (n= 498). Main data were direct cost (€ 2012) 
and Health Related Quality of Life (SF-12). We have calculated the goodness of fit 
for copulas (Gumbel copula, Clayton Copula, Frank Copula, Normal Copula, Plackett 
Copula and T copula) based on the empirical process comparing the empirical cop-
ula with a parametric estimate of the copula derived under the null hypothesis. We 
have used inversion of Kendall’s tau method to fit copulas. A multivariate independ-
ence sample was generated to compare with copulas results. This process was rep-
licated for a 100 times to obtain p-values by bootstrap method. Results: Marginal 
distribution of direct cost was a 3-parameter Gamma distribution (shape= 1.856, 
scale= 0.00324, location= 10.97). Marginal distribution of Health Related Quality of 
Life was associated to a 1- gamma (shape 2.9253 and scale 0.16104). P-value range 
were 0.093 to 0.144 for independent distribution, 0.004 to 0.031 for Gumbel copula, 
0.246 to 0.522 for Clayton Copula, 0.545 to 0.814 for Frank Copula, 0.463 to 0.716 for 
Normal Copula, 0.373 to 0.628 for T Copula and 0.549 to 0.847 for Plackett Copula. 
Frank Copula and Plackett Copula had the best goodness of fit. Kendall’s Tau for 
Fran Copula showed a correlation of -0.4212. cOnclusiOns: Copulas distribution 
allows us to adjust better the non-lineal relation between cost and effectiveness. 
Furthermore, this kind of approach could improve probabilistic sensitivity analyses.
methods have been developed for synthesis of diverse sources of evidence: multiple 
outcomes (including surrogate, potentially short-term endpoints) and other exter-
nal evidence. These methods were applied to an example in rheumatoid arthritis 
where outcomes such as the Health Assessment Questionnaire (HAQ), the Disease 
Activity Score (DAS-28) and the American College of Rheumatology (ACR20) are 
synthesized. External information about correlations between the outcomes was 
included in the form of informative prior distributions. Estimates of HAQ were then 
mapped onto EQ-5D. Also in an alternative approach, the multivariate framework 
was applied to model jointly the utility estimates and the clinical effectiveness out-
comes. Results: The use of multivariate meta-analysis led to reduced uncertainty 
around the effectiveness and utility estimates. Combining the HAQ with DAS-28 
gave a 19% reduction in the uncertainty around the estimate of HAQ and also 16% 
around the estimate of EQ-5D. cOnclusiOns: By allowing all relevant data to be 
incorporated in economic evaluations of new health technologies, this multivariate 
approach to meta-analysis can lead to reduced uncertainty and hence more efficient 
decision-making in health care.
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The usefulness of a multivariate approach to compare treatments in the context of 
pairwise meta-analysis has been widely demonstrated in the literature. However, 
this approach has not yet been considered for multiple treatment comparisons. 
We believe that extending such methodology to network meta-analysis (NMA) 
will increase the primary evidence base allowing us to compare more interven-
tions across multiple outcomes measures. Borrowing strength between outcome 
measures using multivariate NMA can also potentially increase the precision of 
relative treatment effect estimates and reduce the impact of outcome reporting 
bias.Objectives: To extend standard NMA to incorporate multiple outcomes of 
interest and evaluate the use of multivariate NMA models through simulated and 
real datasets. MethOds: We developed a random effects multivariate NMA model 
to account for the correlation between multiple outcome measures. The potential 
benefits of this method were demonstrated in a simulated example comparing uni-
variate and bivariate NMAs for continuous outcome measures. We further explored 
the application of our multivariate NMA model using a case study comparing anti-
obesity pharmacological interventions for waist circumference, weight change and 
BMI change from baseline. Results: The simulation study showed that through 
use of multivariate NMA the precision in mean relative treatment effects increased 
compared to a standard univariate NMA. This held true under multiple scenarios 
testing model parameters including both within- and between-outcome correla-
tions. Similar findings were obtained from the application to the example data-
set in obesity. cOnclusiOns: Our method proves particularly useful in reducing 
uncertainty around relative effectiveness estimates when the outcomes included 
for analysis are highly correlated. However, the advantages of the multivariate NMA 
are limited where there is little correlation between outcome measures. Further 
work will explore the applicability of multivariate NMA methods to different types 
of outcomes such as binary outcome measures.
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Objectives: In multi-centre Time and Motion (T&M) studies, time endpoints can 
be highly variable due to differences in centre practices. Our aim was to assess the 
impact of the type of analysis employed on the results of a T&M study. MethOds: 
Data from 13 centres were analyzed in relation to each of the following: drug prepa-
ration, distribution, and injection, using three methods. Base case methodology 
included a random intercept generalized linear mixed effect model assuming 
gamma distribution with log link function to account for potential centre cluster-
ing effect and non-normality of the outcome measure. The two alternative methods 
were: standard linear regression (assuming time data are normally distributed) and 
gamma regression with log link function (assuming time data are positively skewed), 
both of which do not account for centre clustering effect. Sample means and vari-
ability as measured by 95% confidence interval (CI)) were also compared. Results: 
For the base case, mean time was 0.53 min (95% CI: 0.33-0.85) for “preparation”, 0.30 
min (95% CI: 0.22-0.40) for “distribution”, and 0.81 min (95% CI: 0.59-1.11) for “injec-
tion”. Mean time resulting from the standard linear regression was markedly higher 
for “preparation”: 0.66 (95% CI: 0.59-0.73), and similar for “distribution” and “injec-
tion”: 0.34 (95% CI: 0.30-0.37) and 0.84 minutes (95% CI: 0.79-0.88), respectively. Using 
the gamma regression yielded similar results to standard linear regression: 0.65 (95% 
CI: 0.59-0.71), 0.31 (95% CI: 0.29-0.34), and 0.83 minutes (95% CI: 0.79-0.88), respec-
tively. The base case scenario detected a “centre-clustering” effect, hence producing 
substantially wider CIs compared to both alternative methods which ignore depend-
ence in the data. cOnclusiOns: Although mean task times remained relatively 
stable across the various methods, 95% CIs were substantially wider for random 
intercept model. If “centre-clustering” is detected, random effects regression models 
must be employed to produce valid confidence intervals around point estimates.
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